Results

1–10 of 271 results for Anti-VEGF

Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials
Sharon D. Solomon, MD
Annual Meeting Talks
2023
Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Impact and Outcomes of Anti-VEGF Prior Authorization Requests: Insights From a Large Database Analysis
Saira Khanna, MD
Annual Meeting Talks
2023
Daily Imaging With Home Optical Coherence Tomography Among Treatment-Naive Neovascular Age-Related Macular Degeneration Participants
Kevin J. Blinder, MD, FASRS
Annual Meeting Talks
2023
Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2023
Efficacy and Safety of Biosimilar Ranibizumab-nuna and Ranibizumab-eqrn in Clnical Use by a Consortium of Retina Specialists
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2023
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH
Annual Meeting Talks
2023
Suprachoroidal Delivery of RGX-314 for Neovascular AMD Results of the Phase II AAVIATE Study
David S. Boyer, MD
Annual Meeting Talks
2023
Rates of Post Intravitreal Anti-VEGF Injection Endophthalmitis: Management Strategies and Visual Acuity Outcomes From the AAO IRIS Registry
Alia K Durrani, MD
Annual Meeting Talks
2023